This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Paul M. Ridker, MD; Meir J. Stampfer, MD; Charles H. Hennekens, MD

JAMA. 1995;273(16):1269-1273.

Abstract
Objective.
—To assess prospectively the risk of future stroke associated with baseline concentration of lipoprotein(a), abbreviated Lp(a).

Design.
—Nested case-control study using baseline plasma samples.

Setting.
—Men in the Physicians' Health Study.

Participants.
—A cohort of 14 916 male physicians with no prior history of stroke, transient ischemic attack, or myocardial infarction provided plasma samples at baseline and were followed prospectively for 7.5 years. Samples from 198 physicians who subsequently developed stroke (155 thromboembolic, 35 hemorrhagic, eight indeterminate) were analyzed for Lp(a) concentration together with paired controls, matched for age and smoking habit.

Main Outcome Measure.
—Fatal and nonfatal stroke.

Results.
—Median Lp(a) concentration (8.88 mg/dL [0.23 mmol/L] vs 8.55 mg/dL [0.22 mmol/L]), P=.69) and overall distributions of Lp(a) (P=.54) were similar at baseline in men who did and did not develop future stroke. In analyses controlling for age, smoking status, blood pressure, obesity, and the presence of diabetes, the relative risks (RRs) associated with baseline Lp(a) concentration exceeding the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.26, 0.99,1.06, 0.90, and 1.03 (all P values nonsignificant). There was likewise no association in analyses limited to thromboembolic events. For example, among subjects with baseline Lp(a) values exceeding the 95th percentile of the control distribution, the RR of future thromboembolic stroke was 1.01 (P=.9). No evidence of association between Lp(a) and stroke risk was found in analyses limited to individuals with hypercholesterolemia.

Conclusions.
—Among nearly 15000 predominantly white, healthy, middleaged men followed in the Physicians' Health Study for a period of 7.5 years, we found no evidence of association between baseline plasma concentration of Lp(a) and future risk of total or thromboembolic stroke.

(JAMA. 1995;273:1269-1273)

Author Affiliations
From the Divisions of Preventive Medicine (Drs Ridker and Hennekens), Cardiovascular Disease (Dr Ridker), and the Channing Laboratory (Dr Stampfer), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; the Department of Ambulatory Care and Prevention (Dr Hennekens), Harvard Medical School; and the Departments of Nutrition (Dr Stampfer) and Epidemiology (Drs Stampfer and Hennekens), Harvard School of Public Health, Boston, Mass.

Footnotes
Reprint requests to Brigham and Women's Hospital, 900 Commonwealth Ave, Boston, MA 02115-1204 (Dr Ridker).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lipoprotein(a) and Cardiovascular Disease in Ethnic Chinese: The Chin-Shan Community Cardiovascular Cohort Study
Chien et al.
Clin. Chem. 2008;54:285-291.
ABSTRACT | FULL TEXT  

Lipoprotein (a) and Stroke: A Meta-Analysis of Observational Studies
Smolders et al.
Stroke 2007;38:1959-1966.
ABSTRACT | FULL TEXT  

Plasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular Disease
Jones et al.
Clin. Chem. 2007;53:679-685.
ABSTRACT | FULL TEXT  

Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women.
Suk Danik et al.
JAMA 2006;296:1363-1370.
ABSTRACT | FULL TEXT  

Lipoprotein(a) and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study
Ohira et al.
Stroke 2006;37:1407-1412.
ABSTRACT | FULL TEXT  

Apo(a) size in ischemic stroke: Relation with subtype and severity on hospital admission
Zambrelli et al.
Neurology 2005;64:1366-1370.
ABSTRACT | FULL TEXT  

Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study
Rifai et al.
Clin. Chem. 2004;50:1364-1371.
ABSTRACT | FULL TEXT  

Long-Term Effects of Lipoprotein(a) on Carotid Atherosclerosis in Elderly Japanese
Iwamoto et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2004;59:M62-67.
ABSTRACT | FULL TEXT  

Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly
Ariyo et al.
NEJM 2003;349:2108-2115.
ABSTRACT | FULL TEXT  

Pentanucleotide TTTTA Repeat Polymorphism of Apolipoprotein(a) Gene and Plasma Lipoprotein(a) Are Associated With Ischemic and Hemorrhagic Stroke in Chinese: A Multicenter Case-Control Study in China
Sun et al.
Stroke 2003;34:1617-1622.
ABSTRACT | FULL TEXT  

Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population
Paultre et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:141-146.
ABSTRACT | FULL TEXT  

Apolipoprotein A-I and B and Stroke Events in a Community-Based Cohort in Taiwan: Report of the Chin-Shan Community Cardiovascular Study
Chien et al.
Stroke 2002;33:39-44.
ABSTRACT | FULL TEXT  

Lipoprotein(a) and Cognitive Performances in an Elderly White Population : Cross-Sectional and Follow-Up Data
Sarti et al.
Stroke 2001;32:1678-1683.
ABSTRACT | FULL TEXT  

Lipoprotein (a) and stroke
Milionis et al.
J. Clin. Pathol. 2000;53:487-496.
ABSTRACT | FULL TEXT  

Lipoprotein(a) and the Risk of Stroke
Wityk and Kittner
Stroke 2000;31 :1194-1198.
FULL TEXT  

Chlamydia pneumoniae Antibodies and High Lipoprotein(a) Levels Do Not Predict Ischemic Cerebral Infarctions : Results From a Nested Case-Control Study in Northern Sweden
Glader et al.
Stroke 1999;30:2013-2018.
ABSTRACT | FULL TEXT  

Defensin Promotes the Binding of Lipoprotein(a) to Vascular Matrix
Bdeir et al.
Blood 1999;94:2007-2019.
ABSTRACT | FULL TEXT  

Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen
Harjai
ANN INTERN MED 1999;131:376-386.
ABSTRACT | FULL TEXT  

Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks?
Ridker
ANN INTERN MED 1999;130:933-937.
ABSTRACT | FULL TEXT  

Hyperhomocysteinemia and Hypofibrinolysis in Young Adults With Ischemic Stroke
Kristensen et al.
Stroke 1999;30:974-980.
ABSTRACT | FULL TEXT  

The Use of Multisite High Resolution Arterial Imaging to Assess Arteriosclerosis
Vagnini et al.
ANGIOLOGY 1997;48:1023-1030.
ABSTRACT  

Predictive Value of Electrophoretically Detected Lipoprotein(a) for Coronary Heart Disease and Cerebrovascular Disease in a Community-Based Cohort of 9936 Men and Women
Nguyen et al.
Circulation 1997;96:1390-1397.
ABSTRACT | FULL TEXT  

Defensin Stimulates the Binding of Lipoprotein (a) to Human Vascular Endothelial and Smooth Muscle Cells
Higazi et al.
Blood 1997;89:4290-4298.
ABSTRACT | FULL TEXT  

Lipoprotein(a) in Stored Plasma Samples and the Ravages of Time: Why Epidemiological Studies Might Fail
Kronenberg et al.
Arterioscler. Thromb. Vasc. Bio. 1996;16:1568-1572.
ABSTRACT | FULL TEXT  

Lipoprotein(a) in Patients With Acute Cerebral Ischemia
van Kooten et al.
Stroke 1996;27:1231-1235.
ABSTRACT | FULL TEXT  

Lipoprotein(a) Concentration and Risk of Atherothrombotic Disease
Craig and Bostom
JAMA 1995;274:1198-1198.
ABSTRACT  

Lipoprotein(a) Concentration and Risk of Atherothrombotic Disease-Reply
Ridker et al.
JAMA 1995;274:1198-1199.
ABSTRACT